Post-surgical eye inflammation is one of the most common complications facing the roughly 4 million Americans who undergo cataract surgery each year. How quickly and completely that inflammation resolves directly affects visual recovery, patient comfort, and long-term outcomes — making a new Phase 3 candidate with strong efficacy data clinically significant for a large and aging population.
Across two identically designed, multicenter, randomized, double-masked, placebo-controlled Phase 3 trials enrolling 748 participants, clobetasol propionate ophthalmic suspension (CPN) 0.05% — dosed as one drop twice daily for 14 days — demonstrated statistically significant superiority over placebo on both co-primary endpoints. By postoperative day 15, 58.2% of patients receiving CPN achieved complete clearance of anterior chamber cells (a direct measure of intraocular inflammation) compared with just 17.3% in the placebo arm — a more than threefold difference. Pain elimination followed a similarly robust pattern, with meaningful separation from placebo emerging as early as day 4 and sustained through day 15. A corneal endothelial cell safety substudy embedded in the second trial found no clinically meaningful cell loss attributable to the drug, addressing a key concern for any topical corticosteroid used post-cataract surgery.
Clobetasol propionate is among the most potent topical corticosteroids available in dermatology, and its ophthalmic formulation has been carefully titrated to 0.05% for ocular use — a concentration that appears to balance anti-inflammatory potency with an acceptable intraocular pressure profile over a two-week course. Current standard-of-care post-cataract drops typically include prednisolone acetate or difluprednate, both of which carry IOP elevation risks, particularly in steroid responders. Whether CPN's IOP profile is meaningfully differentiated from these agents in real-world, longer-term use remains an open question this trial's 22-day follow-up cannot fully resolve. The trials excluded complicated surgeries, limiting generalizability to higher-risk cases. Nonetheless, the combination of large sample size, rigorous Phase 3 design, and dual-trial replication marks this as more than incremental — it represents a credible new entrant in a therapeutic category that directly impacts recovery quality for millions of cataract patients annually.